Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Asuka Wada

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes

Drugs in R and D

Pharmacology

2016

English

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects With Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in Its Glycemic Efficacy

Drugs in R and D

Pharmacology

2017

English

Related publications

Impact of Cancer on Use of Glucose-Lowering Drug Treatment in Individuals With Diabetes: Potential Mechanisms

English

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

Journal of Clinical Medicine Research

2016

English

Changes in Blood Pressure and Body Weight Over Ten Years in Men Selected for Glucose Intolerance.

Journal of Epidemiology and Community Health

English

Peculiarities of Metabolic Factors of Cardiovascular Risk in Essential Hypertension Patients Depending on Body Weight and Gender

Ukraïnsʹkij žurnal medicini, bìologìï ta sportu

2020

English

Effect of Clothing Weight on Body Weight

International Journal of Obesity

English

Sustained Effect of Glucagon on Body Weight and Blood Glucose: Assessed by Continuous Glucose Monitoring in Diabetic Rats

PLoS ONE

Multidisciplinary

2018

English

Dosing Obese Cats Based on Body Weight Spuriously Affects Some Measures of Glucose Tolerance

Domestic Animal Endocrinology

English

Therapy Focused on Lowering Postprandial Glucose, Not Fasting Glucose, May Be Superior for Lowering HbA1c. IOEZ Study Group

English

Distinct Glucose Lowering and Beta Cell Protective Effects of Vanadium and Food Restriction in Streptozotocin-Diabetes

European Journal of Endocrinology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Asuka Wada

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes

Canagliflozin as an Initial Therapy in Drug-Naïve Subjects With Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in Its Glycemic Efficacy

Related publications

Impact of Cancer on Use of Glucose-Lowering Drug Treatment in Individuals With Diabetes: Potential Mechanisms

Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study

Changes in Blood Pressure and Body Weight Over Ten Years in Men Selected for Glucose Intolerance.

Peculiarities of Metabolic Factors of Cardiovascular Risk in Essential Hypertension Patients Depending on Body Weight and Gender

Effect of Clothing Weight on Body Weight

Sustained Effect of Glucagon on Body Weight and Blood Glucose: Assessed by Continuous Glucose Monitoring in Diabetic Rats

Dosing Obese Cats Based on Body Weight Spuriously Affects Some Measures of Glucose Tolerance

Therapy Focused on Lowering Postprandial Glucose, Not Fasting Glucose, May Be Superior for Lowering HbA1c. IOEZ Study Group

Distinct Glucose Lowering and Beta Cell Protective Effects of Vanadium and Food Restriction in Streptozotocin-Diabetes